How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,181 results for

Hepatotoxic Medication

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

2161. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. (PubMed)

Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Telithromycin is a ketolide antibiotic approved by the U.S. Food and Drug Administration for acute bacterial infections causing sinusitis, bronchitis, and community-acquired pneumonia.To describe 3 cases of severe hepatotoxicity in patients receiving telithromycin.Case reports.A tertiary care medical center.3 previously healthy patients who had recently taken telithromycin and took no other (...) . The frequency of severe telithromycin-related hepatotoxicity cannot be established with case reports.Telithromycin can cause severe hepatotoxicity. Caution is advised in prescribing this drug pending additional postmarketing surveillance data.

2006 Annals of Internal Medicine

2162. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. (PubMed)

Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. To determine whether inactive hepatitis B surface antigen (HBsAg) carriers are at a higher risk of drug-induced hepatotoxicity than control subjects during antituberculosis treatment with standard short-course regimens of isoniazid, rifampin, ethambutol, and/or pyrazinamide.Retrospective case-control study.Tertiary university medical center.One hundred ten inactive HBsAg carriers (...) who received standard antituberculosis medication were selected as control subjects.The baseline characteristics of the 110 inactive HBsAg carriers were similar to those of the 97 noncarriers. A total of 85% of persons in both groups had received an initial treatment regimen that included pyrazinamide. Thirty-eight inactive HBsAg carriers (35%) and 19 control subjects (20%) exhibited elevated liver enzyme levels during antituberculosis treatment (p = 0.016). Drug-induced hepatotoxicity, which

2005 Chest

2163. An official ATS statement: hepatotoxicity of antituberculosis therapy. (PubMed)

An official ATS statement: hepatotoxicity of antituberculosis therapy. Drug-induced liver injury (DILI) is a problem of increasing significance, but has been a long-standing concern in the treatment of tuberculosis (TB) infection. The liver has a central role in drug metabolism and detoxification, and is consequently vulnerable to injury. The pathogenesis and types of DILI are presented, ranging from hepatic adaptation to hepatocellular injury. Knowledge of the metabolism of anti-TB medications (...) and of the mechanisms of TB DILI is incomplete. Understanding of TB DILI has been hampered by differences in study populations, definitions of hepatotoxicity, and monitoring and reporting practices. Available data regarding the incidence and severity of TB DILI overall, in selected demographic groups, and in those coinfected with HIV or hepatitis B or C virus are presented. Systematic steps for prevention and management of TB DILI are recommended. These include patient and regimen selection to optimize benefits

2006 American Journal of Respiratory and Critical Care Medicine

2164. Review article: drug hepatotoxicity. (PubMed)

Review article: drug hepatotoxicity. Drug toxicity is the leading cause of acute liver failure in the United States. Further understanding of hepatotoxicity is becoming increasingly important as more drugs come to market.(i) To provide an update on recent advances in our understanding of hepatotoxicity of select commonly used drug classes. (ii) To assess the safety of these medications in patients with pre-existing liver disease and in the post-liver transplant setting. (iii) To review relevant (...) advances in toxicogenomics which contribute to the current understanding of hepatotoxic drugs.A Medline search was performed to identify relevant literature using search terms including 'drug toxicity, hepatotoxicity, statins, thiazolidinediones, antibiotics, antiretroviral drugs and toxicogenomics'.Amoxicillin-clavulanic acid is one of the most frequently implicated causes of drug-induced liver injury worldwide. Statins rarely cause clinically significant liver injury, even in patients with underlying

Full Text available with Trip Pro

2007 Alimentary Pharmacology & Therapeutics

2165. Hepatotoxicity of drugs used for treatment of obesity and its comorbidities. (PubMed)

Hepatotoxicity of drugs used for treatment of obesity and its comorbidities. Obesity is an increasingly prevalent problem with many associated health risks. Obese patients may present with liver diseases directly attributable to their obesity, such as nonalcoholic steatohepatitis (NASH). However, many such individuals are prescribed various potentially hepatotoxic medications for obesity itself, as well as for the complications of obesity. Clinically, it may be difficult to distinguish the two (...) . Furthermore, many of these medications are in common use, and some are not commonly recognized as potentially injurious to the liver. While some medications have predictable hepatotoxicity, many more have associated idiosyncratic reactions. We review the literature and case-reports of hepatotoxicity associated with four categories of medications: those used primarily in the treatment of obesity, those used in the treatment of diabetes mellitus, those used in the treatment of hyperlipidemia, and those used

2004 Seminars in Liver Disease

2166. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. (PubMed)

as definite or probable on the Council for International Organizations of Medical Sciences (CIOMS) scale were collated and compared to published case series. Hepatotoxicity related to amoxicillin-clavulanate was identified in 69 patients (36 males; mean age 56 years) representing 14% of all cases of hepatotoxicity submitted to the Registry. There was an overall sex distribution and the predominant pattern of lesion was hepatocellular (36%) which occurred at a shorter duration of treatment (P < .03). Mean (...) Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. Amoxicillin-clavulanate (AC) hepatotoxicity has been reported to exhibit a higher predominance of cholestatic types of damage, especially in males. However, the determinants of its clinical expression are unknown. This study prospectively evaluated the profile of AC hepatotoxicity. Data on all cases of hepatotoxicity reported to the Spanish Registry attributed to AC and assessed

Full Text available with Trip Pro

2006 Hepatology

2167. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. (PubMed)

suggest that the lopinavir/RTV is not associated with a significantly increased risk of hepatotoxity among HCV-infected and uninfected patients compared with an alternative PI-based regimen, nelfinavir. Accordingly, other medication-related factors (e.g, efficacy and non-hepatic toxicity) should guide individual treatment decisions. (...) Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. To determine the incidence of significant liver enzyme elevations following the initiation of protease inhibitor (PI)-based antiretroviral therapy (ART) with or without pharmacokinetic boosting with ritonavir (RTV), and to define the role of chronic viral hepatitis in its development.Prospective, cohort analysis of 1161 PI-naive, HIV-infected patients receiving RTV-boosted

2004 AIDS

2168. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. (PubMed)

and laboratory monitoring.We included subjects with baseline and follow-up alanine transaminase and aspartate aminotransferase tests. Severe hepatotoxicity cases were identified during the first 12 months of ART. Potential risk factors, including concomitant medication use, tuberculosis, and hepatitis B and C, were determined from clinical records, database queries, and serological testing. Associations with hepatotoxicity were investigated using Cox proportional hazards modeling.Of the 868 subjects (94 (...) Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. Hepatotoxicity is a significant complication of antiretroviral therapy (ART). We assessed the incidence of and risk factors for hepatotoxicity among HIV-infected individuals on ART in South Africa.We conducted a retrospective cohort study in a workplace HIV care program in South Africa which uses a first-line regimen of efavirenz, zidovudine, and lamivudine and provides routine clinical

Full Text available with Trip Pro

2007 AIDS

2169. Systematic review: hepatotoxic events associated with herbal medicinal products. (PubMed)

Library, Amed and Ciscom. To identify additional data, searches were conducted by hand in relevant medical journals and in our own files. The screening and selection of articles and the extraction of data were performed independently by the two authors. There were no restrictions regarding the language of publication. In order to be included articles were required to report data on hepatotoxic events associated with the therapeutic use of herbal medicinal products.Single medicinal herbs (...) Systematic review: hepatotoxic events associated with herbal medicinal products. Large proportions of patients use herbal medicinal products, and encouraging data in terms of effectiveness exist for some of these. One aspect, however, which is still largely under-investigated is the question of potential harm.To review the recent evidence on hepatotoxic events associated with the use of herbal medicinal products.Systematic literature searches were performed on Medline, Embase, The Cochrane

2003 Alimentary pharmacology & therapeutics

2170. Nefazodone (Serzone) withdrawn because of hepatotoxicity (PubMed)

Nefazodone (Serzone) withdrawn because of hepatotoxicity 14638657 2004 01 08 2018 11 30 0820-3946 169 11 2003 Nov 25 CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne CMAJ Nefazodone (Serzone) withdrawn because of hepatotoxicity. 1187 Choi Stephen S eng Journal Article Canada CMAJ 9711805 0820-3946 0 Antidepressive Agents, Second-Generation 0 Piperazines 0 Triazoles 59H4FCV1TF nefazodone AIM IM Antidepressive Agents, Second-Generation adverse effects

Full Text available with Trip Pro

2003 CMAJ: Canadian Medical Association Journal

2171. Severe Hepatotoxicity in a Rheumatoid Arthritis Patient Switched From Leflunomide to Methotrexate (PubMed)

Severe Hepatotoxicity in a Rheumatoid Arthritis Patient Switched From Leflunomide to Methotrexate 16369235 2006 07 13 2018 12 03 1531-0132 7 3 2005 Sep 06 MedGenMed : Medscape general medicine MedGenMed Severe hepatotoxicity in a rheumatoid arthritis patient switched from leflunomide to methotrexate. 9 Gupta Rachna R Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India. Gupta S K SK eng Case Reports Journal Article 2005 09 06 United States MedGenMed 100894134

Full Text available with Trip Pro

2005 Medscape General Medicine

2172. Effectiveness and hepatotoxicity of statins in men seropositive for hepatitis C virus. (PubMed)

Effectiveness and hepatotoxicity of statins in men seropositive for hepatitis C virus. To evaluate the effectiveness and hepatotoxicity of statins in patients who are seropositive for hepatitis C virus (HCV).Retrospective review of a registry of patients with HCV.Veterans Affairs Medical Center.One hundred forty-six male patients who were seropositive for HCV and had received statin therapy between January 1, 1995, and September 9, 2003.Demographic and clinical data were collected for each

2007 Pharmacotherapy

2173. Severe hepatotoxicity associated with the dietary supplement LipoKinetix. (PubMed)

Severe hepatotoxicity associated with the dietary supplement LipoKinetix. LipoKinetix (Syntrax, Cape Girardeau, Missouri) is a dietary supplement marketed for weight loss.To describe a possible causal association between LipoKinetix and hepatotoxicity.Case series.Outpatient clinic, tertiary care hospital, and U.S. Food and Drug Administration databases.Routine medical and supportive care.Clinical and laboratory evaluation.All patients developed acute hepatotoxicity within 3 months of starting (...) of LipoKinetix may be associated with hepatotoxicity. Despite extensive evaluations, no other cause for hepatotoxicity could be identified in the seven patients studied.

2002 Annals of Internal Medicine

2174. Hepatotoxicity in patients with juvenile idiopathic arthritis receiving longterm methotrexate therapy. (PubMed)

Hepatotoxicity in patients with juvenile idiopathic arthritis receiving longterm methotrexate therapy. To evaluate hepatotoxicity in patients with juvenile idiopathic arthritis (JIA) receiving methotrexate (MTX) therapy with doses of 20-30 mg/m2 of body surface area.We graded the histology of percutaneous liver biopsies from 34 patients with JIA receiving longterm (> 2.4 years) MTX therapy at the Rheumatism Foundation Hospital, Heinola, Finland, using the Roenigk classification scale. Medical (...) records of the patients with JIA were retrospectively analyzed.Of 10 patients with MTX doses >/= 20 mg/m2, 4 had grade II, 5 had grade I histology, and one specimen with extensive steatosis as the only pathologic finding could not be classified. All 24 patients treated with low dose MTX had grade I histology. No specimen showed fibrosis or cirrhosis. In 2 patients with grade II histology, extensive portal tract inflammation resolved when MTX was discontinued for 6 months.Aggressive medical treatment

2002 Journal of Rheumatology

2175. Probable quinine-induced hepatotoxicity. (PubMed)

Probable quinine-induced hepatotoxicity. 8128710 1994 04 13 2018 11 13 0093-0415 160 1 1994 Jan The Western journal of medicine West. J. Med. Probable quinine-induced hepatotoxicity. 59-60 Perez J A JA Jr Department of Medicine, Kern Medical Center, Bakersfield, CA 93305. Stryker J J Arsura E L EL Hewitt J M JM eng Case Reports Journal Article United States West J Med 0410504 0093-0415 A7V27PHC7A Quinine AIM IM Aged Chemical and Drug Induced Liver Injury Humans Male Quinine adverse effects 1994

Full Text available with Trip Pro

1994 Western Journal of Medicine

2176. Hepatotoxic reaction to chloroquine phosphate in a patient with previously unrecognized porphyria cutanea tarda. (PubMed)

Hepatotoxic reaction to chloroquine phosphate in a patient with previously unrecognized porphyria cutanea tarda. 7618323 1995 08 22 2018 11 13 0093-0415 162 6 1995 Jun The Western journal of medicine West. J. Med. Hepatotoxic reaction to chloroquine phosphate in a patient with previously unrecognized porphyria cutanea tarda. 548-51 Liu A C AC Palo Alto Medical Foundation, CA 94022, USA. eng Case Reports Journal Article United States West J Med 0410504 0093-0415 0 Antimalarials 0 Coproporphyrins

Full Text available with Trip Pro

1995 Western Journal of Medicine

2177. Paracetamol concentrations, hepatotoxicity, and antidotes. (PubMed)

Paracetamol concentrations, hepatotoxicity, and antidotes. 7353114 1980 04 25 2013 11 21 0007-1447 280 6207 1980 Jan 12 British medical journal Br Med J Paracetamol concentrations, hepatotoxicity, and antidotes. 114 Gilligan J E JE Kemp R R Pain R R Phillips P J PJ eng Letter England Br Med J 0372673 0007-1447 362O9ITL9D Acetaminophen AE28F7PNPL Methionine WYQ7N0BPYC Acetylcysteine AIM IM Acetaminophen blood poisoning Acetylcysteine therapeutic use Humans Methionine therapeutic use Risk Time

Full Text available with Trip Pro

1980 British medical journal

2178. Hepatotoxicity of erythromycin ethylsuccinate in a child. (PubMed)

Hepatotoxicity of erythromycin ethylsuccinate in a child. 6603894 1983 10 08 2018 11 13 0008-4409 129 5 1983 Sep 01 Canadian Medical Association journal Can Med Assoc J Hepatotoxicity of erythromycin ethylsuccinate in a child. 411-2 Phillips K G KG eng Case Reports Letter Canada Can Med Assoc J 0414110 0008-4409 1014KSJ86F Erythromycin Ethylsuccinate 63937KV33D Erythromycin AIM IM Child Cough drug therapy Erythromycin adverse effects analogs & derivatives Erythromycin Ethylsuccinate Humans

Full Text available with Trip Pro

1983 Canadian Medical Association Journal

2179. Unusual hepatotoxic reaction to quinidine. (PubMed)

Unusual hepatotoxic reaction to quinidine. 6704857 1984 05 21 2018 11 13 0008-4409 130 8 1984 Apr 15 Canadian Medical Association journal Can Med Assoc J Unusual hepatotoxic reaction to quinidine. 973 Hogan D B DB Morin J J Crilly R G RG eng Case Reports Letter Canada Can Med Assoc J 0414110 0008-4409 ITX08688JL Quinidine AIM IM Aged Atrial Flutter drug therapy Cholestasis, Intrahepatic chemically induced Humans Male Quinidine adverse effects 1984 4 15 1984 4 15 0 1 1984 4 15 0 0 ppublish

Full Text available with Trip Pro

1984 Canadian Medical Association Journal

2180. Reversible hepatotoxicity related to amphotericin B. (PubMed)

Reversible hepatotoxicity related to amphotericin B. Hepatotoxicity is regarded as a rare side effect of amphotericin B therapy. A patient with acute myelogenous leukemia who had normal liver function was treated with amphotericin B for fungal pneumonia. While he was receiving the drug at high dosages asymptomatic elevation of the levels of alkaline phosphatase, serum glutamic oxaloacetic transaminase, serum glutamic pyruvic transaminase, lactic dehydrogenase and bilirubin was noted. The levels (...) returned to normal when the drug was discontinued. Rechallenge with a lower dosage prompted a rapid rise in the levels, with subsequent return to normal when the medication was withdrawn.

Full Text available with Trip Pro

1984 Canadian Medical Association Journal

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>